ER Reactivation Therapy for Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 11, 2016

Primary Completion Date

January 5, 2024

Study Completion Date

July 5, 2024

Conditions
Metastatic Breast Cancer
Interventions
DRUG

17B-estradiol

Anti-estrogen

DRUG

Letrozole

Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

DRUG

Anastrozole

Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

DRUG

Exemestane

Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

Trial Locations (3)

55905

Mayo Clinic Cancer Center, Rochester

01199

Baystate Medical Center, Springfield

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT02188745 - ER Reactivation Therapy for Breast Cancer | Biotech Hunter | Biotech Hunter